{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:27:42Z","timestamp":1780378062576,"version":"3.54.1"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Universal leucocyte depletion reduces the risk of transfusion\u2010transmitted cytomegalovirus; however, many clinicians still prescribe cytomegalovirus seronegative units.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Our retrospective study aims to confirm the low risk of transfusion\u2010transmitted cytomegalovirus with leucocyte depletion alone and demonstrate the ongoing variability in cytomegalovirus seronegative transfusion prescribing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Over a 9\u2010year period (July 2009\u2013July 2018), occurrences of transfusion transmitted cytomegalovirus in cytomegalovirus seronegative donor\/recipient haemopoietic stem cell transplant pairs were compared at one allogeneic haemopoietic stem cell transplant centre providing cytomegalovirus seronegative blood products and leucocyte depletion (double prevention) versus another providing leucocyte depletion only (single prevention). Retrospective chart audit identified patient demographics, blood product exposure and cytomegalovirus infection by polymerase chain reaction. A separate audit examined cytomegalovirus seronegative blood product ordering in a broader range of hospital types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 122 and 66 cytomegalovirus\u2010negative donor\/recipient haemopoietic stem cell transplant pairs using double and single transfusion prevention strategy respectively. Transfusion exposure to red cells and pooled platelets was similar, although more apheresis platelets were used in the double prevention group. The cytomegalovirus infection rate was 3 (2.4%) and zero in the double and single prevention groups respectively. Cytomegalovirus seronegative unit ordering was not limited to hospitals with obstetric or neonatal populations, suggesting ongoing reliance of cytomegalovirus seronegative units outside this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The analysis suggests a double prevention strategy does not provide additional protection against transfusion\u2010transmitted cytomegalovirus. There is ongoing variability in the acceptance of leucocyte depletion alone despite the low risk of cytomegalovirus infection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.15751","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T09:39:33Z","timestamp":1648028373000},"page":"717-722","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["C<scp>entre\u2010based<\/scp> comparison of double versus single prevention strategy on transfusion\u2010<scp>transmitted cytomegalovirus<\/scp> in <scp>at\u2010risk<\/scp> haemopoietic stem cell transplant patients and a state survey on cytomegalovirus<scp>\u2010seronegative<\/scp> ordering practises"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-6335","authenticated-orcid":false,"given":"Daniela","family":"Zantomio","sequence":"first","affiliation":[{"name":"Pathology Services Australian Red Cross Lifeblood  Australia"},{"name":"Department of Haematology Austin Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bayly","sequence":"additional","affiliation":[{"name":"Pathology Services Australian Red Cross Lifeblood  Australia"},{"name":"Laboratory Haematology Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Wong","sequence":"additional","affiliation":[{"name":"Pathology Services Australian Red Cross Lifeblood  Australia"},{"name":"Laboratory Haematology Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplant Alfred Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morgan","sequence":"additional","affiliation":[{"name":"Laboratory Haematology Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Laboratory Haematology Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Laboratory Haematology Alfred Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta M.","family":"Dennington","sequence":"additional","affiliation":[{"name":"Pathology Services Australian Red Cross Lifeblood  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04845.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8050685"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598"},{"key":"e_1_2_6_5_1","unstructured":"European committee on blood transfusion.Guide to the preparation use and quality assurance of blood components.Recommendation no R (95) 15. 20th edn. Strabourge France: European Directorate for the Quality of Medicines & HealthCare of the Council of Europe2020195\u2010245."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15344"},{"key":"e_1_2_6_7_1","unstructured":"Australian and New Zealand Society of Blood Transfusion (ANZSBT).Guideline for transfusion and immunohaematology laboratory practice. ANZSBT. 1st edn revised.2020[cited 2021 Jul 1]. Available from URL:https:\/\/anzsbt.org.au\/wp-content\/uploads\/2021\/04\/Guideline_-for_Transfusion_and_Immunohaematology_Laboratory_Practice_FINAL_Published_20210426.pdf"},{"key":"e_1_2_6_8_1","unstructured":"National Blood authority (NBA).Position paper. Clinical use of cytomegalovirus seronegative blood products in Australia. NBA;2017[cited 2021 Jul 10]. Available from URL:https:\/\/www.blood.gov.au\/system\/files\/documents\/cmv-blood-components.pdf"},{"key":"e_1_2_6_9_1","unstructured":"Advisory Committee on the Safety of Blood Tissues and Orgabs (SaBTO).Cytomegalovirus tested blood components: Position statement. [cited 2021 Mar 15]. Available from URL:https:\/\/www.gov.uk\/government\/publications\/sabto-report-of-the-cytomegalovirus-steering-group"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw181"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9185"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1734"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080412"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.013"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03203.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12219"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01306.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12250"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.15751","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.15751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:36:50Z","timestamp":1692455810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.15751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/imj.15751"],"URL":"https:\/\/doi.org\/10.1111\/imj.15751","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"2021-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}